Cargando…
培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较
BACKGROUND AND OBJECTIVE: At present, there is no standard salvage treatment strategies for lung cancer. The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxaliplatin as salvage therapy in stage Ⅳ lung adenocarcinoma to provide evidence...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999616/ https://www.ncbi.nlm.nih.gov/pubmed/21924035 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.01 |
_version_ | 1783331453137846272 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: At present, there is no standard salvage treatment strategies for lung cancer. The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxaliplatin as salvage therapy in stage Ⅳ lung adenocarcinoma to provide evidences for combination therapy. METHODS: From January 2009 to February 2011, 83 patients with stage Ⅳ lung adenocarcinoma received pemetrexed alone (single agent arm, n=47) or pemetrexed combined with oxaliplatin (combination arm, n=36) as salvage therapy. All 83 patients had performance status (PS) scores of 0-2. RESULTS: Eighty-one patients were included in the final analysis. The median progression-free survival (PFS) in the single agent arm was 3.6 months versus 4.1 months in the combination arm (P=0.268). The objective response rate (ORR) was 6.5% versus 20% (P=0.092), and the disease control rate (DCR) was 56.5% versus 65.7% (P=0.493), respectively. The response rates of the hematological and gastrointestinal toxicities in the single agent and combination arms were 33.9% versus 47.2% (P=0.460) and 21.2% versus 25.0% (P=0.213), respectively. CONCLUSION: For salvage therapy, pemetrexed combined with oxaliplatin is tolerable in stage Ⅳ lung adenocarcinoma patients with good PS scores. Compared with pemetrexed alone, pemetrexed combined with oxaliplatin therapy showed higher response rate, but did not significantly prolong the PFS. |
format | Online Article Text |
id | pubmed-5999616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59996162018-07-06 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: At present, there is no standard salvage treatment strategies for lung cancer. The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxaliplatin as salvage therapy in stage Ⅳ lung adenocarcinoma to provide evidences for combination therapy. METHODS: From January 2009 to February 2011, 83 patients with stage Ⅳ lung adenocarcinoma received pemetrexed alone (single agent arm, n=47) or pemetrexed combined with oxaliplatin (combination arm, n=36) as salvage therapy. All 83 patients had performance status (PS) scores of 0-2. RESULTS: Eighty-one patients were included in the final analysis. The median progression-free survival (PFS) in the single agent arm was 3.6 months versus 4.1 months in the combination arm (P=0.268). The objective response rate (ORR) was 6.5% versus 20% (P=0.092), and the disease control rate (DCR) was 56.5% versus 65.7% (P=0.493), respectively. The response rates of the hematological and gastrointestinal toxicities in the single agent and combination arms were 33.9% versus 47.2% (P=0.460) and 21.2% versus 25.0% (P=0.213), respectively. CONCLUSION: For salvage therapy, pemetrexed combined with oxaliplatin is tolerable in stage Ⅳ lung adenocarcinoma patients with good PS scores. Compared with pemetrexed alone, pemetrexed combined with oxaliplatin therapy showed higher response rate, but did not significantly prolong the PFS. 中国肺癌杂志编辑部 2011-09-20 /pmc/articles/PMC5999616/ /pubmed/21924035 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.01 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 |
title | 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 |
title_full | 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 |
title_fullStr | 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 |
title_full_unstemmed | 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 |
title_short | 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ期肺腺癌挽救性治疗的比较 |
title_sort | 培美曲赛单药与培美曲赛联合奥沙利铂用于ⅳ期肺腺癌挽救性治疗的比较 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999616/ https://www.ncbi.nlm.nih.gov/pubmed/21924035 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.01 |
work_keys_str_mv | AT péiměiqūsàidānyàoyǔpéiměiqūsàiliánhéàoshālìbóyòngyúivqīfèixiànáiwǎnjiùxìngzhìliáodebǐjiào AT péiměiqūsàidānyàoyǔpéiměiqūsàiliánhéàoshālìbóyòngyúivqīfèixiànáiwǎnjiùxìngzhìliáodebǐjiào AT péiměiqūsàidānyàoyǔpéiměiqūsàiliánhéàoshālìbóyòngyúivqīfèixiànáiwǎnjiùxìngzhìliáodebǐjiào AT péiměiqūsàidānyàoyǔpéiměiqūsàiliánhéàoshālìbóyòngyúivqīfèixiànáiwǎnjiùxìngzhìliáodebǐjiào AT péiměiqūsàidānyàoyǔpéiměiqūsàiliánhéàoshālìbóyòngyúivqīfèixiànáiwǎnjiùxìngzhìliáodebǐjiào AT péiměiqūsàidānyàoyǔpéiměiqūsàiliánhéàoshālìbóyòngyúivqīfèixiànáiwǎnjiùxìngzhìliáodebǐjiào |